The High Authority for Health (HAS) issued an unfavorable opinion on Thursday on the use of Valneva’s VLA2001 vaccine for primary vaccination once morest Covid.
“There are no clinical efficacy data or immunological data with the current variants. Therefore, it has not been retained for the moment.t”, explained Elisabeth Bouvet, president of the Technical Commission for Vaccinations (CTV) of the HAS, during a press conference.
“It did not seem wise to give it a place in France, we consider that we have enough vaccines available for people who do not want mRNA vaccination”she added.
Inactivated vaccine
Last June, Valneva obtained marketing authorization from the European Medicines Agency (EMA) for its inactivated vaccine candidate once morest COVID-19.
At the same time, HAS issued a favorable opinion on Thursday on the booster use in adults of the VidPrevtyn Beta vaccines from Sanofi/GSK ( ) and Nuvavoxd from Novavax.
In his communiquél’institution “reaffirms the importance of the reminder: it is the best weapon to protect people at risk of a severe form of the disease and must be carried out without delay by people over 60, those with comorbidities, pregnant women as well as the people who accompany them on a daily basis, including health professionals.”
